Hims & Hers, Inc. discovered a data breach on February 5, 2026, affecting its computer network through a compromised Zendesk customer service platform. Between February 4-7, 2026, unauthorized users accessed customer service tickets containing personal information including names, contact details, and other sensitive data. Edelson Lechtzin LLP is investigating class action claims on behalf of affected individuals.
Hims & Hers Health, Inc. (HIMS)
Common Stock · Currency in USD · XNYS
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Company Info
SIC8011
Composite FIGIBBG00Q53VYM7
CIK0001773751
IPOJan 21, 2021
Sectorservices-offices & clinics of doctors of medicine
Highlights
Market Cap$4.36B
EPS$0.28
P/E Ratio69.14
Revenue$2.29B
Gross Profit$1.77B
Net Income$63.10M
Employees2,442
WSO227,938,766
Phone415-851-0195
Websitehttps://www.forhims.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Hims & Hers Health, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Hims & Hers Health, Inc. (HIMS) has returned -42.00% so far this year and -21.88% over the past 12 months. Looking at the last ten years, HIMS has achieved an annualized return of 1.15%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
HIMS
1M15.79%
6M-64.30%
YTD-42.00%
1Y-21.88%
5Y8.04%
10Y1.15%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Hims & Hers Health, Inc. (HIMS) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.91% | -46.44% | 43.07% | -8.86% | ||||||||
| 2025 | 51.42% | 28.79% | -34.29% | 11.43% | 67.73% | -12.44% | 35.50% | -34.41% | 37.20% | -18.68% | -15.22% | -16.21% |
| 2024 | -2.50% | 51.63% | 17.55% | -19.94% | 56.36% | 1.05% | 4.12% | -29.59% | 25.73% | 1.78% | 69.58% | -27.95% |
| 2023 | 27.38% | 36.11% | -13.74% | 16.83% | -22.80% | 5.74% | -5.08% | -24.10% | -8.04% | -5.53% | 48.91% | -0.22% |
| 2022 | -25.84% | 5.67% | 2.90% | -22.18% | -3.12% | 12.41% | 37.56% | 4.09% | -10.43% | -19.79% | 33.69% | 2.56% |
| 2021 | 11.18% | -24.51% | -14.76% | -6.99% | 16.77% | -24.37% | -27.76% | -1.50% | -4.56% | 3.31% | -16.24% | -0.76% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Hims & Hers Health, Inc. (HIMS) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of HIMS compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Hims & Hers Health, Inc. volatility is 10.36%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 2.15B | 707.54M | 441.19M | 366.34M | 420.59M |
| Temporary Equity Attributable To Parent (USD) | - | - | - | - | - |
| Temporary Equity (USD) | - | - | - | - | - |
| Equity Attributable To Parent (USD) | 540.93M | 476.72M | 344.03M | 311.74M | 334.62M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - |
| Equity (USD) | 540.93M | 476.72M | 344.03M | 311.74M | 334.62M |
| Noncurrent Liabilities (USD) | 1.21B | 9.46M | 8.69M | 6.66M | 6.75M |
| Other Current Liabilities (USD) | 245.05M | 118.12M | 37.51M | 10.58M | 56.22M |
| Wages (USD) | 16.10M | 12.07M | 7.89M | 5.00M | 3.36M |
| Accounts Payable (USD) | 143.28M | 91.18M | 43.07M | 32.36M | 19.64M |
| Current Liabilities (USD) | 404.43M | 221.37M | 88.47M | 47.94M | 79.22M |
| Liabilities (USD) | 1.61B | 230.82M | 97.16M | 54.60M | 85.97M |
| Other Non-current Assets (USD) | 1.19B | 268.30M | 157.56M | 124.91M | 122.59M |
| Intangible Assets (USD) | 196.12M | 43.41M | 18.57M | 21.84M | 25.89M |
| Fixed Assets (USD) | - | - | - | 3.00M | 2.20M |
| Noncurrent Assets (USD) | 1.39B | 311.71M | 176.13M | 149.75M | 150.68M |
| Other Current Assets (USD) | 649.62M | 315.23M | 231.92M | 184.64M | 251.74M |
| Prepaid Expenses (USD) | 37.89M | 16.17M | 10.67M | 10.39M | 4.61M |
| Inventory (USD) | 80.13M | 64.43M | 22.46M | 21.56M | 13.56M |
| Current Assets (USD) | 767.64M | 395.83M | 265.05M | 216.60M | 269.91M |
| Assets (USD) | 2.15B | 707.54M | 441.19M | 366.34M | 420.59M |
News and Insights
Novo Nordisk launched a subscription program for Wegovy (semaglutide) starting March 31, 2026, offering tiered pricing to reduce costs for self-pay patients. Monthly prices range from $329 to $249 for injections (up to $1,200 annual savings) and $289 to $249 for oral versions through telehealth partners including Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame expected to join later. The program aims to improve treatment adherence and address cost barriers.
Following the expiration of India's semaglutide patent, over 40 Indian pharmaceutical companies have launched generic versions of Novo Nordisk's Ozempic and Wegovy at dramatically reduced prices—approximately 70% cheaper than originals. Major players like Sun Pharmaceutical, Dr. Reddy's Laboratories, and Zydus Lifesciences are offering monthly treatments ranging from $7.99 to $44.73, with plans to expand into global markets including Canada, Brazil, and Latin America as the obesity market is projected to reach $100 billion by decade's end.
The FDA approved Wegovy HD (semaglutide) 7.2 mg, a higher-dose version of Novo Nordisk's weight-loss drug, for patients who have tolerated the standard 2.4 mg dose. The approval is based on the STEP UP clinical trial showing significant weight loss benefits. Wegovy HD will be available starting in April across 70,000+ U.S. pharmacies. Despite the approval, Novo Nordisk shares declined 2.05% at the time of publication.
The article identifies the top 10 most heavily shorted stocks as of March 11, 2026, with Lucid Group leading the list. It explains why stocks become heavily shorted, the mechanics of short squeezes, and notes that while high short interest can signal potential volatility and upside moves, timing such trades is challenging and investors should conduct thorough due diligence given the underlying business risks.
BLKBRD Asset Management fully liquidated its 318,666 shares of Hims & Hers Health (worth ~$18.07 million) in Q4 2025, representing a complete exit from a position that was 5.0% of the fund's AUM. The stock had plummeted 72.46% over the past year following Novo Nordisk's partnership termination and lawsuit. However, on March 10, 2026, Hims & Hers announced a new partnership with Novo Nordisk to offer weight-loss drugs Ozempic and Wegovy, causing the stock to surge 6% as the lawsuit was dropped.
European natural gas prices surged to three-year highs amid US-Israeli military operations against Iran, with the Dutch TTF rising 68% weekly due to supply disruption concerns. Europe remains politically divided on the strikes, with the UK, France, and Spain taking more cautious stances while Germany and Eastern Europe support US-Israeli actions. Weak industrial production data across the Euro Area and UK signals fragile economic growth, while energy price spikes threaten to accelerate inflation and complicate ECB policy decisions.
Hims & Hers stock surged 40% after announcing a deal with Novo Nordisk to sell Wegovy pills and Ozempic injections on its platform. The agreement resolves a major legal overhang from a February lawsuit and removes uncertainty around the companies' relationship. Despite the sharp price increase, the stock remains attractively valued at under 20x forward P/E, though investors should exercise caution given the volatile history between the two companies.
Hims & Hers Health and Novo Nordisk have resolved their legal dispute over patent violations and announced a partnership to sell weight-loss drugs through Hims & Hers' telehealth platform. While the company beat earnings expectations (8 cents vs. 3 cents estimated), Q1 and 2026 revenue guidance fell short of analyst estimates. HIMS shares surged 48.67% in premarket trading, though technical indicators show mixed signals with the stock trading well above its 20-day moving average but below its 100-day average.
U.S. stock futures fell sharply on Monday as oil prices surged amid Iran-US conflict, with Brent Crude jumping 14.90% to $106.50 and WTI rising 13.27% to $102.96. Major indices declined with Dow Jones down 1.61%, S&P 500 down 1.41%, and Nasdaq 100 down 1.56%. President Trump dismissed the spike as temporary. Notable movers included Hims & Hers surging 49.36% after resolving disputes with Novo Nordisk, and UniQure gaining 35.88% on FDA clarity regarding its Huntington's disease therapy.